Michael S. Ryan Inc. Increases Position in Merck & Co., Inc. (NYSE:MRK)

Michael S. Ryan Inc. boosted its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 4.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,553 shares of the company’s stock after purchasing an additional 179 shares during the quarter. Merck & Co., Inc. comprises 0.4% of Michael S. Ryan Inc.’s portfolio, making the stock its 29th largest position. Michael S. Ryan Inc.’s holdings in Merck & Co., Inc. were worth $468,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of MRK. Marquette Asset Management LLC purchased a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $26,000. Your Advocates Ltd. LLP purchased a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $28,000. Ruedi Wealth Management Inc. grew its holdings in shares of Merck & Co., Inc. by 180.2% during the third quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after buying an additional 200 shares during the last quarter. Level Financial Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 45.5% during the second quarter. Level Financial Advisors Inc. now owns 320 shares of the company’s stock valued at $37,000 after buying an additional 100 shares during the last quarter. Finally, Activest Wealth Management purchased a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 74.59% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 43,823 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a total transaction of $4,602,729.69. Following the completion of the transaction, the executive vice president now directly owns 111,764 shares of the company’s stock, valued at $11,738,572.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Richard R. Deluca sold 43,823 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $105.03, for a total transaction of $4,602,729.69. Following the completion of the transaction, the executive vice president now directly owns 111,764 shares of the company’s stock, valued at $11,738,572.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johannes Jacobus Oosthuizen sold 2,081 shares of Merck & Co., Inc. stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $102.38, for a total transaction of $213,052.78. Following the completion of the transaction, the insider now directly owns 18,191 shares of the company’s stock, valued at $1,862,394.58. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of research analyst reports. StockNews.com initiated coverage on shares of Merck & Co., Inc. in a research report on Thursday, October 5th. They set a “buy” rating on the stock. TD Cowen upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $125.00 to $135.00 in a research report on Thursday, January 4th. Truist Financial restated a “buy” rating and set a $122.00 price objective on shares of Merck & Co., Inc. in a research report on Friday, October 6th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Merck & Co., Inc. in a research report on Thursday, November 9th. They set a “buy” rating and a $115.00 price objective on the stock. Finally, BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and set a $132.00 price objective on the stock in a research report on Friday, October 27th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $125.65.

Read Our Latest Research Report on MRK

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $118.15 on Thursday. The firm has a fifty day moving average price of $107.51 and a 200-day moving average price of $106.87. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.38 and a quick ratio of 1.12. The stock has a market cap of $299.39 billion, a PE ratio of 65.63, a price-to-earnings-growth ratio of 1.62 and a beta of 0.35. Merck & Co., Inc. has a 1 year low of $96.36 and a 1 year high of $119.94.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.19. The firm had revenue of $16 billion during the quarter, compared to analysts’ expectations of $15.30 billion. Merck & Co., Inc. had a net margin of 7.77% and a return on equity of 18.26%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.85 earnings per share. Equities analysts anticipate that Merck & Co., Inc. will post 1.38 earnings per share for the current fiscal year.

Merck & Co., Inc. Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, January 8th. Investors of record on Friday, December 15th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.61%. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.73. The ex-dividend date was Thursday, December 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 171.11%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.